The global cutaneous leishmaniasis drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Cutaneous leishmaniasis spreads by the bite of sandflies and primarily affects the skin. Its drugs are generally effective and work well against the parasites causing leishmaniasis. The major factors that are driving the growth of the global cutaneous leishmaniasis drugs market include the growing prevalence of parasitic infections among the global population, ease of direct purchase due to the access to OTC drugs, and the constant innovations and developments of drugs. The prevalence of leishmaniasis is highly subject to environmental factors coupled with natural conditions. Areas with rich vegetation and climatic factors are majorly responsible for the spread of sandflies and the subsequent outbreak of leishmaniasis. For instance, as per the World Health Organization (WHO), it is anticipated that between 600,000 to 1.0 million new global cases of leishmaniasis occur yearly.
The approved drugs for cutaneous leishmaniasis treatment are majorly fluconazole, impavido, pentam 300 solution, diflucan tablet azole antifungals-systemic, miltefosine capsule, and pentamidine 300 mg solution for injection antiprotozoal agents. However, cutaneous leishmaniasis can be prevented with the support of prophylactic vaccines. The development and consumption of such vaccines support in controlling the disease. Thus, such development is expected to have a positive impact on the overall market growth.
Market Coverage
Competitive Landscape: GlaxoSmithKline plc, Pfizer Inc., and Novartis International AG, among others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Cutaneous Leishmaniasis Drugs Market Report by Segment
By Type
• Pentavalent Antimonials
• Antifungal Drugs
• Anti-Leishmanial/Antimicrobial Drugs
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Global Cutaneous Leishmaniasis Drugs Market by Region
North America
Europe
Asia-Pacific
Rest of the World